



Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study

Tadashi Terui¹ · Yukari Okubo² · Satomi Kobayashi³ · Shigetoshi Sano⁴ · Akimichi Morita⁵ · Shinichi Imafuku⁶ · Yayoi Tada⁷ · Masatoshi Abe⁸ · Masafumi Yaguchi⁹ · Natsuka Uehara⁹ · Takahiro Handa⁹ · Masayuki Tanaka⁹ · Wendy Zhang¹⁰ · Maria Paris¹⁰ · Masamoto Murakami¹¹

Published online: 7 December 2023
© Springer Nature Switzerland AG 2023

Author Correction: American Journal of Clinical Dermatology (2023) 24:837-847
<https://doi.org/10.1007/s40257-023-00788-2>

Page 840, Table 1 Baseline Patient Demographics and Clinical Characteristics

(ITT Population):

‘PPPASI score categories at randomization, n (%)’ section, ‘≤ 20’ row: The cell entry in the ‘Placebo’ column, which previously read:

“15 (34.1)”

should read:

“14 (31.8)”

‘PPPASI score categories at randomization, n (%)’ section, ‘≥ 21 to ≤ 30’ row: The cell entry in the ‘Placebo’ column, which previously read:

“18 (40.9)”

should read:

“19 (43.2)”

The original article can be found online at <https://doi.org/10.1007/s40257-023-00788-2>.

✉ Tadashi Terui
terui.tadashi@nihon-u.ac.jp

¹ Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi, Tokyo 173-8610, Japan

² Tokyo Medical University, Tokyo, Japan

³ Seibo International Catholic Hospital, Tokyo, Japan

⁴ Kochi Medical School, Kochi University, Kochi, Japan

⁵ Nagoya City University, Nagoya, Japan

⁶ Fukuoka University, Fukuoka, Japan

⁷ Teikyo University, Tokyo, Japan

⁸ Sapporo Skin Clinic, Sapporo, Japan

⁹ Amgen K.K., Tokyo, Japan

¹⁰ Amgen Inc., Thousand Oaks, CA, USA

¹¹ Ehime University Graduate School of Medicine, Ehime, Japan

‘Focal infection status at randomization, n (%)’ section, ‘Presence’ row: The cell entry in the ‘Placebo’ column, which previously read:

“34 (77.3)”

should read:

“32 (72.7)”

‘Focal infection status at randomization, n (%)’ section, ‘Absence’ row: The cell entry in the ‘Placebo’ column, which previously read:

“10 (22.7)”

should read:

“12 (27.3)”

'Focal infection status at randomization, n (%)' section, 'Presence' row: The cell entry in the 'Apremilast 30 mg BID' column, which previously read:

“37 (80.4)”

should read:

“32 (69.6)”

'Focal infection status at randomization, n (%)' section, 'Absence' row: The cell entry in the 'Apremilast 30 mg BID' column, which previously read:

“9 (19.6)”

should read:

“14 (30.4)”

The corrected Table 1 is as follows:

Table 1 Baseline patient demographics and clinical characteristics (ITT population)

	Placebo (n=44)	Apremilast 30 mg BID (n=46)
Age, years		
N	44	46
Mean (SD)	54.7 (11.68)	54.9 (11.30)
Sex, n (%)		
Male	11 (25.0)	10 (21.7)
Female	33 (75.0)	36 (78.3)
BMI, kg/m ²		
N	44	46
Mean (SD)	25.33 (5.309)	24.37 (3.732)
Tobacco use, n (%)		
User	38 (86.4)	37 (80.4)
Non-user	6 (13.6)	9 (19.6)
Duration of PPP, years		
N	44	46
Mean (SD)	7.53 (9.026)	7.34 (8.627)
PPPASI score categories at randomization, n (%)		
≤20	14 (31.8)	16 (34.8)
≥21 to ≤30	19 (43.2)	18 (39.1)
≥31	11 (25.0)	12 (26.1)
PPSI total score		
N	44	46
Mean (SD)	8.2 (1.5)	8.3 (1.5)

	Placebo (n=44)	Apremilast 30 mg BID (n=46)
PGA, n (%)		
2	1 (2.3)	3 (6.5)
3	24 (54.5)	16 (34.8)
4	17 (38.6)	21 (45.7)
5	2 (4.5)	6 (13.0)
Pruritus VAS		
N	42	46
Mean (SD)	57.0 (27.8)	50.3 (31.6)
Pain VAS		
N	42	46
Mean (SD)	50.3 (30.0)	45.4 (31.9)
DLQI total score		
N	43	46
Mean (SD)	7.2 (4.7)	7.5 (4.9)
Focal infection status at randomization, n (%)		
Presence	32 (72.7)	32 (69.6)
Absence	12 (27.3)	14 (30.4)

APR apremilast 30 mg twice daily, BMI body mass index, PBO placebo, PPP palmoplantar pustulosis, PPPASI Palmoplantar Pustular Area and Severity Index, SD standard deviation

Page 841, Fig. 1 legend:

The footnote that previously read:

“*Two-sided P-value (nominal) is based on chi-square test. Missing data were imputed by nonresponder imputation.”

should read:

“*Two-sided P-value is based on chi-square test. Missing data were imputed by nonresponder imputation.”

Page 841, Fig. 1:

The text above the PPPASI-50 columns that previously read:

“Treatment difference: 37.4% (95% CI: 18.6%, 56.1%) Nominal P=0.0003*”

should read:

“Treatment difference: 37.4% (95% CI: 18.6%, 56.1%) P=0.0003*”

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative

Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.